GABA A signalling is involved in N/OFQ anxiolytic-like effects but not in nocistatin anxiogenic-like action as evaluated in the mouse elevated plus maze

• Published in: Peptides (New York, N.Y. : 1980) Vol. 29; no. 8; pp. 1404 - 1412
• Main Authors: Gavioli, Elaine C., Duarte, Filipe S., Guerrini, Remo, Calo, Girolamo, Rae, Giles A., M. De Lima, Thereza C.
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01-08-2008
• Subjects: Animals; Anti-Anxiety Agents - pharmacology; Anxiety; Diazepam - pharmacology; Dose-Response Relationship, Drug; GABA A receptor ligands; GABA-A Receptor Agonists; Ligands; Male; Maze Learning - drug effects; Mice; Mouse; Nociceptin; Nociceptin/orphanin FQ; Nocistatin; NOP receptor; Opioid Peptides - pharmacology; Receptors, GABA-A - drug effects; Signal Transduction - drug effects; Vasodilator Agents - pharmacology; ppN/OFQ; Mouse; N/OFQ; i.c.v; i.p; Anxiety; Nociceptin/orphanin FQ; GABA A receptor ligands; Nocistatin; NOP receptor
• ISSN: 0196-9781; 1873-5169
• DOI: 10.1016/j.peptides.2008.04.004

Nociceptin/orphanin FQ (N/OFQ) and nocistatin are two neuropeptides originated from the same precursor prepronociceptin/orphanin FQ (ppN/OFQ). N/OFQ is the endogenous ligand of the NOP receptor, while the target of action of nocistatin is still unknown. N/OFQ modulates various biological functions, including anxiety. Conversely, nocistatin either behaves as a functional N/OFQ antagonist or evokes per se effects opposite to those of N/OFQ. Here we investigated the interaction between the anxiolytic-like effects of N/OFQ and the anxiogenic-like action of nocistatin with those evoked by GABA
A receptor ligands in the mouse elevated plus maze. The anxiogenic-like effects of the GABA
A receptor antagonist pentylenetetrazol (20
mg/kg; intraperitoneal, i.p.) were abolished by the co-treatment with N/OFQ (10
pmol; intracerebroventricular, i.c.v.) while potentiated by the administration of nocistatin (0.01
pmol; i.c.v.). The anxiolytic-like effects of the benzodiazepine receptor agonist diazepam (0.75
mg/kg, i.p.) were reversed by nocistatin (0.1
pmol; i.c.v.), whereas signs of sedation were observed when mice were co-treated with diazepam and N/OFQ (3
pmol). Interesting enough, the i.p. treatment with flumazenil (1
mg/kg) blocked the anxiolytic-like effects of N/OFQ (10
pmol; i.c.v.), but not the anxiogenic effect elicited by nocistatin. Collectively, our findings suggest that the effects on anxiety elicited by pentylenetetrazol and diazepam can be counteracted or potentiated in the presence of N/OFQ and nocistatin. In addition, the effects on anxiety of N/OFQ, but not nocistatin, appear to be dependent on the benzodiazepine site of the GABA
A receptor.